IDivine

CorrectSequence Therapeutics, also known as iDivine Biotech, is a clinical-stage biotechnology company pioneering the development of next-generation gene editing therapies. The company utilizes its proprietary iDivine platform—standing for "intelligent Design of in vivo integrated nucleotide editing"—to create highly precise base editors and prime editors. Their lead program, CS-101, recently demonstrated clinical success as the world's first base-editing therapy to treat transfusion-dependent β-thalassemia. CorrectSequence focuses on treating genetic diseases through permanent DNA correction with significantly reduced off-target risks compared to traditional CRISPR methods. Headquartered in Shanghai and Suzhou, the company is supported by leading venture capital firms including Qiming Venture Partners and Lilly Asia Ventures.